文献速递血脂与心血管预防肺血管病与心包/心肌炎

贝派地酸降低他汀不耐受患者静脉血栓栓塞风险:CLEAR Outcomes随机临床试验事后分析

Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

IMPORTANCE: Venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, is a frequent condition that can lead to significant morbidity and mortality; statins, monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, an…

要点

  • 贝派地酸与静脉血栓栓塞风险降低相关(HR 0.58,95%CI 0.39-0.86)。
  • 深静脉血栓(HR 0.56)和肺栓塞(HR 0.61)结果与主要复合终点一致。
  • 该分析针对他汀不耐受且心血管高危或已确诊动脉粥样硬化性心血管疾病人群。

核心结论

  • 在他汀不耐受且心血管高危或已确诊动脉粥样硬化性心血管疾病的参与者中,贝派地酸治疗与静脉血栓栓塞风险降低相关。

研究设计与样本

  • CLEAR Outcomes为随机、双盲、安慰剂对照的心血管结局临床试验。
  • 2016年12月22日至2019年8月14日在32个国家1250个中心入组18至85岁他汀不耐受且心血管高危或已确诊动脉粥样硬化性心血管疾病的个体。
  • 本分析为事后分析,统计分析方法于2025年3月10日至2026年2月19日进行。

主要发现

  • 随机分组时275例(2.0%)有静脉血栓栓塞病史,1219例(8.7%)正在接受全身抗凝治疗。

临床怎么用

  • 对于他汀不耐受且心血管高危或已确诊动脉粥样硬化性心血管疾病的患者,贝派地酸在降低心血管事件的同时可能降低静脉血栓栓塞风险。

局限性

  • 本分析为CLEAR Outcomes试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, is a frequent condition that can lead to significant morbidity and mortality; statins, monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, and their combination are associated with a reduced risk of VTE. The effect of bempedoic acid on VTE risk is unknown. OBJECTIVE: To determine whether bempedoic acid is associated with a reduced risk of VTE. DESIGN, SETTING, AND PARTICIPANTS: CLEAR Outcomes was a randomized, double-blind, placebo-controlled, cardiovascular outcomes clinical trial. Statin-intolerant individuals at high risk for or with established atherosclerotic cardiovascular disease who were aged 18 to 85 years were enrolled between December 22, 2016, and August 14, 2019, in 1250 centers across 32 countries. The statistical analysis for the present study was conducted between March 10, 2025, and February 19, 2026. INTERVENTIONS: Participants were randomized to oral bempedoic acid, 180 mg, or placebo daily. MAIN OUTCOMES AND MEASURES: The main outcome for this analysis was the time to first occurrence of VTE (composite of deep vein thrombosis or pulmonary embolism). The occurrences of deep vein thrombosis and pulmonary embolism were also assessed. RESULTS: A total of 13 970 participants (mean [SD] age, 65.5 [9.0] years; 6740 [48.2%] female) were randomized, 6992 to bempedoic acid and 6978 to placebo. At the time of randomization, 275 participants (2.0%) had a history of VTE, and 1219 (8.7%) were receiving systemic anticoagulation. The participants were followed up for a median (IQR) of 40.6 (37.1-46.2) months. A total of 106 VTE events occurred (39 in the bempedoic acid group and 67 in the placebo group; hazard ratio [HR], 0.58; 95% CI, 0.39-0.86; P = .006). Findings were consistent for deep vein thrombosis (HR, 0.56; 95% CI, 0.31-0.996; P = .045) and pulmonary embolism (HR, 0.61; 95% CI, 0.37-0.996; P = .046). CONCLUSIONS AND RELEVANCE: Treatment with bempedoic acid among participants with statin intolerance at high risk for or with established cardiovascular disease was associated with a reduced risk of VTE. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02993406.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Spiazzi BF, Brennan D, Zingano CP, et al. Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42201706. doi:10.1001/jamacardio.2026.1208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。